The Effects of Anti-obesity Pharmacotherapy Interventions on Psychosocial Factors Among Adolescents with Obesity: a Scoping Review

Jackson R. Dillard, Faith A. Newsome, Aaron S. Kelly, Amy C. Gross, Jane Morgan-Daniel, Lauren E. Adkins, Sweta S. Madem, Michelle I. Cardel

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of Review: The purpose of this review was to investigate and synthesize psychosocial outcomes from pharmacotherapy experimental trials for weight loss among adolescents with obesity. Recent Findings: There is a paucity of research regarding pharmacological interventions for adolescents with obesity. These studies have typically reported reductions in weight, and side effects have been inconsistently described. Overall, medication seems to be a safe and effective obesity treatment modality for adolescents with obesity. Summary: Six articles were included in this review. Studies varied in medication type, medication dosing, lifestyle components, psychosocial measures, measurement intervals, and psychosocial outcomes. All studies found a reduction in weight and/or BMI. Studies were often underpowered to detect differences in psychosocial variables, which were always considered secondary or exploratory outcomes. Future research should include psychosocial outcomes as a primary endpoint of pharmacological interventions for adolescent obesity. Ultimately, the treatment of the complex disease of obesity deserves to be assessed through multiple health domains extending beyond weight reduction.

Original languageEnglish (US)
Pages (from-to)58-70
Number of pages13
JournalCurrent Nutrition Reports
Volume10
Issue number1
DOIs
StatePublished - Mar 2021

Bibliographical note

Funding Information:
Dr. Cardel is supported by the National Institute of Health National Heart, Lung, and Blood Institute (K01HL141535 and R25HL126146) and the National Center for Advancing Translational Sciences (UL1TR001427).

Funding Information:
Aaron S. Kelly has served as an unpaid consultant for Novo Nordisk, Vivus, and Weight Watchers, and has been provided drugs/placebo from AstraZeneca to conduct a clinical trial funded by the National Institutes of Health (NIH).

Funding Information:
Michelle I. Cardel is supported by grants from the NIH National Heart, Lung, and Blood Institute and the National Center for Advancing Translational Sciences and WellCare Health Plans, Inc.; has received compensation from Weight Watchers for service as a consultant; and has received non-financial support from Novo Nordisk.

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Keywords

  • Adolescent obesity
  • Pharmacological interventions
  • Psychosocial outcomes

PubMed: MeSH publication types

  • Journal Article
  • Review

Fingerprint Dive into the research topics of 'The Effects of Anti-obesity Pharmacotherapy Interventions on Psychosocial Factors Among Adolescents with Obesity: a Scoping Review'. Together they form a unique fingerprint.

Cite this